G - Physics – 01 – N
Patent
G - Physics
01
N
G01N 33/574 (2006.01) G01N 33/573 (2006.01)
Patent
CA 2233687
The present invention relates to a method for diagnosing prostatic adenocarcinoma (CAP) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml and 20.2 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA (10) to total PSA (12) is calculated. If this proportion is less than about 7 %, then the patient is diagnosed as having CAP. The present method can also be used on patients that have a total PSA of at least 10.1 ng/ml, but have also had a negative prostate biopsy.
L'invention porte sur une méthode diagnostique de carcinome prostatique (CAP) chez un sujet humain sans recours à une biopsie. On mesure tout d'abord le niveau total d'antigène prostatique spécifique (PSA) présent dans le sang ou le sérum du sujet. Si le sujet a un niveau total de PSA compris entre 2,5 ng/ml et 20,2 ng/ml, on mesure alors le niveau libre de PSA présent dans le sang ou le sérum du sujet, puis on calcule le rapport entre PSA libre (10) et PSA total (12). Si ce rapport est inférieur à environ 7 %, le diagnostic est que le sujet présente un CAP. Ladite méthode peut également être utilisée chez des sujets ayant un PSA total d'au moins 10,1 ng/ml, mais pour lesquels une biopsie de la prostate a été négative.
Carlson Grant D.
Luderer Albert A.
Soriano Thomas F.
Thiel Robert F.
Ya-Ting Chen
Dianon Systems Inc.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Novel methods for diagnosing prostatic adenocarcinoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel methods for diagnosing prostatic adenocarcinoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel methods for diagnosing prostatic adenocarcinoma will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1836313